TGA / PMDA / NMPA · Asia-Pacific
stro- — TGA / PMDA / NMPA regulatory status
stro- regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 475 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 0.9% Sodium Chloride Solution, Glenzocimab | Phase 3 | PARItec | 2024-514352-32-00 |
| 1821-FSH-301 | Phase 3 | Fulcrum Therapeutics | 2024-512737-33-00 |
| 2015-1949 | Phase 3 | Ultragenyx UK | NCT02778867 |
| 20210096 | Phase 3 | Amgen | 2023-505457-40-00 |
| 20210098 | Phase 3 | Amgen | 2023-505458-16-00 |
| 2mg Baricitinib | Phase 3 | Chinese Academy of | NCT07449910 |
| 4045-301 | Phase 3 | Sarepta Therapeutics | 2024-514698-23-00 |
| 8951-CL-0301 | Phase 3 | Astellas Pharma | 2024-511365-11-00 |
| 8951-CL-0302 | Phase 3 | Astellas Pharma | 2024-511648-16-00 |
| 8951-CL-0305 | Phase 3 | Astellas Pharma | 2024-519773-19-00 |
| APHP220832 | Phase 3 | PARItec | 2023-507660-39-00 |
| Actovegin | Phase 3 | Takeda | NCT01582854 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2026044005 | PARTICULES DE VAA COMPRENANT DES PEPTIDES CONTENANT RGD POUR ADMINISTRER DES CHARGES UTILES DE DYSTROPHINE | WO |
| 12415794 | Pyridazinone compounds and uses thereof | US |
| 12403203 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | US |
| 12397062 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | US |
| 12377150 | Exon skipping oligomer conjugates for muscular dystrophy | US |
| 12379385 | Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function | US |
| 12329824 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | US |
| 12280122 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | US |
| 12275937 | Stereospecific linkages in RNA editing oligonucleotides | US |
| 12240831 | Pyridazinone compounds and uses thereof | US |
| 12240833 | Pyridazinone compounds and uses thereof | US |
| 12239716 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of stro-?
stro- currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get stro- regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to stro-?
This spoke lists 475 published programs associated with stro- in our pipeline index.